Agios Pharmaceuticals reported Q4 2024 financial results with PYRUKYND net revenue of $10.7 million. The company's cash, cash equivalents, and marketable securities totaled $1.5 billion as of December 31, 2024. Agios completed enrollment for the Phase 3 RISE UP study of Mitapivat in Sickle Cell Disease and filed for regulatory approval of Mitapivat for the treatment of adult patients with thalassemia in multiple regions.
PYRUKYND generated $10.7 million in net revenue, a 20% increase from Q3 2024.
Regulatory applications for mitapivat (PYRUKYND) were filed for the treatment of adult patients with thalassemia.
Enrollment completed for the Phase 3 RISE UP study of mitapivat in sickle cell disease.
Cash, cash equivalents, and marketable securities totaled $1.5 billion as of December 31, 2024.
Agios expects to achieve key milestones in 2025, including receiving an FDA regulatory decision for PYRUKYND in thalassemia and announcing topline results from the Phase 3 RISE UP study of mitapivat in sickle cell disease.
Analyze how earnings announcements historically affect stock price performance